pig vacine

1ASX ANNOUNCEMENT New Vaccine For Major Pig Disease Completes Successful Animal Trials
April 29th, 2004, Sydney:
Imugene today announced that recently completed animal trials have proven the
efficacy of a new vaccine developed by Imugene for controlling one of the worlds
major pig diseases.

The successful pig trials demonstrated that the vaccine prevented the disease
known as Porcine Reproductive & Respiratory Syndrome (PRRS) in all
vaccinated pigs. This disease is one of the most economically important diseases
of pigs worldwide and currently available vaccines have limited efficacy.

The search for an effective vaccine has been a major focus of research by
animal health companies in all major pig producing countries. There has been
significant difficulty in developing safe and effective vaccines using existing
scientific methodology. The basis for the efficacy of the new Imugene PRRS
vaccine is the patented "Adenoviral Delivery Vector".

Preliminary estimates indicate an effective PRRS vaccine would earn revenue of
up to US$100 million pa. If eradication programs were introduced, revenue could
be as much as US$200-300million pa. The total market size for a PRRS vaccine
is difficult to estimate accurately, as the incidence of the disease is increasing.
Estimates of the current economic impact of PRRS on pig producers range
between US$0.5 - 1 billion pa.

Imugene Managing Director Dr Warwick Lamb said "These trials are a major
success for Imugene. The preliminary results indicate our vaccine is highly
effective in protecting pigs exposed to PRRS. One of Imugene's key strategies is
to develop effective vaccines against emerging diseases or diseases for which
effective vaccines are lacking. New effective vaccines against these diseases
generally have rapid market acceptance with high market penetration. The trial
success for our PRRS vaccine is a significant and valuable addition to our
"Adenoviral Vector Delivery" product portfolio."

The PRRS vaccine has now moved into the full product development and
commercialisation process.